Clinical Trials | June 15, 2024
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
10+ emerging markets, Japan & ANZ transition in final phase
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Subscribe To Our Newsletter & Stay Updated
